Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis

Lucie Ellis, based in the UK, joined the SCRIP Intelligence team in 2012. In her current position as a Creative Content Reporter, she is focused on introducing innovative and imaginative ways to display content on the web and routinely annoys SCRIP’s technology and design teams by thinking too far outside of the box. As a reporter covering the pharma and biotech world, Lucie understandably spends a lot of her time writing about drugs and money or Googling abbreviations. However she has a particular interest in employment trends, social and digital media use by industry, patient-centricity, big data, and clinical research in the metabolic and CNS fields. Lucie enjoys traveling and can often be seen out and about at industry events across the globe as SCRIP’s roving reporter.
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

Brexit Ambiguity A Top Priority For Bayer's New UK & Ireland CEO

Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.

Brexit Business Strategies

Smooth AdCom Passage Expected For Novo's Semaglutide Despite Retinopathy Queries

Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.

Metabolic Disorders Advisory Committees

Ipsen To File Cabozantinib For Liver Cancer In 1H 2018

Exelixis and Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer. 

Cancer Clinical Trials

Harmony Biosciences Raises $270m; Acquires US Rights To Narcolepsy Drug

Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018. 

Financing Deals

Can Medtech Firm Locate Solve A Cell Therapy Conundrum?

The time is right for emerging UK medtech firm Locate Therapeutics, a company developing technology that could improve the way impending cell and gene therapies are delivered to patients.

StartUps and SMEs Regenerative Medicine

Vaximm Seeks Funding to Pursue Cancer Vaccine Goals

Privately held Vaximm is seeking investment for its clinical pipeline that includes cancer vaccine VMX01, which is in Phase II as a monotherapy and due to start clinical trials next year in combination with Merck KGaA and Pfizer's PD-L1 inhibitor, Bavencio. 

ImmunoOncology Cancer
See All